SEC Form 4 · accession 0001209191-19-004609
TETRAPHASE PHARMACEUTICALS INC · TTPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Larry Tsai
Officer — Chief Medical Officer
Period of report
Jan 17, 2019
Accepted (ET)
Jan 18, 2019 · 6:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001373707
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 6, 2019 | A | 3,337 | — | A | 31,503 | D | |
| Common StockF2 | May 14, 2018 | A | 2,058 | — | A | 33,561 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF3,F4 | — | Jan 17, 2019 | A | 40,000 | A | — | — | Common Stock | 40,000 | 40,000 | D |
| Restricted Stock UnitsF3,F5 | — | Jan 17, 2019 | A | 140,000 | A | — | — | Common Stock | 140,000 | 140,000 | D |
Explanation of responses
- F1On January 6, 2016, the Reporting person was granted 8,000 restricted stock units ("RSUs")( the "2016 RSU grant") that were previously reported on Table II Of Form 4, which form was filed with the Securities and Exchange Commission on January 4, 2018. Of the 2016 RSU grant, an aggregate of 5,333 shares vested on January 6, 2018 and January 6, 2019 of which an aggregate of 1,996 shares were withheld by the Issuer to satisfy the reporting person's tax withholding obligations in connection with the delivery of the conversion of the RSUs into common stock on such vesting dates. The total number of shares beneficially owned by the reporting person includes the aggregate 3,337 RSUs converted into shares of common stock of the Issuer on each of the January 2018 and January 2019 vesting dates.
- F2The amount of securities beneficially owned by the reporting person following the transaction reported on this Form 4 reflects the purchase by the reporting person of 2,058 shares of common stock on May 14, 2018 pursuant to the issuer's 2014 Employee Stock Purchase Plan.
- F3Each restricted stock unit represents a contingent right to receive one share of common stock of Tetraphase Pharmaceuticals, Inc. for no consideration.
- F4These restricted stock units shall be earned upon achievement of certain performance conditions and, if earned, shall vest on various dates beginning no earlier than March 1, 2020 and ending no later than March 1, 2022.
- F5The restricted stock units vest in three equal installments on each of January 17, 2020, January 17, 2021 and January 17, 2022.